Analyst Ratings For Catabasis Pharmaceuticals (NASDAQ:CATB)
Today, Wedbush reiterated its Outperform rating on Catabasis Pharmaceuticals (NASDAQ:CATB) with a price target of $4.00.
Some recent analyst ratings include
- 2/14/2018-Wedbush Reiterated Rating of Outperform.
- 11/20/2017-Citigroup Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 10/6/2017-Cowen Reiterated Rating of Market Perform.
- 10/5/2017-CIBC Reiterated Rating of Outperform .
Recent Insider Trading Activity For Catabasis Pharmaceuticals (NASDAQ:CATB)
Catabasis Pharmaceuticals (NASDAQ:CATB) has insider ownership of 40.70% and institutional ownership of 32.38%.
- On 6/30/2015 Medimmune Ventures, Inc., Major Shareholder, bought 223,439 with an average share price of $12.00 per share and the total transaction amounting to $2,681,268.00.
- On 6/30/2015 Nicholas Galakatos, Director, bought 376,695 with an average share price of $12.00 per share and the total transaction amounting to $4,520,340.00.
Recent Trading Activity for Catabasis Pharmaceuticals (NASDAQ:CATB)
Shares of Catabasis Pharmaceuticals closed the previous trading session at 1.43 down -0.13 8.33% with 1376695 shares trading hands.
